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To the Editor: Dawson et al. propose circulating tumor DNA as a new biomarker for metastatic breast cancer. In our opinion, the timing of the analysis is crucial for the correct interpretation of such data obtained from samples acquired during chemotherapy.
Apoptosis leads to the augmented release of cell-free DNA, 1 so chemotherapy is expected to temporarily increase the levels of circulating tumor DNA. Thus, the assumption that such increases reflect tumor load may be incorrect, depending on the time point chosen.
We suggest a dual role for analysis with circulating tumor DNA. First, the difference between basal levels before and peak levels after the administration of chemotherapy may serve as an indicator of tumor responsiveness. Second, levels of circulating tumor DNA measured several days after the last chemotherapy cycle may serve as a surrogate marker for total tumor mass.
Analysis detection of circulating tumor DNA over the enumeration of circulating tumor cells by means of the CellSearch System. Our findings provide the rationale for future studies to address the full clinical utility of analyses with circulating tumor DNA. One apparent limitation of our work was that only two genes (PIK3CA and TP53) were analyzed for most patients. These are the two most commonly mutated genes in breast cancer, and as expected, they were informative in half the patients recruited. This does not represent a general limitation of circulating tumor DNA: as a proof of principle, we also found that we were able to monitor other somatic mutations and structural variants in a subset of patients who did not have mutations in PIK3CA or TP53. Our data indicate that any cancer-specific mutation can be monitored in circulating tumor DNA from patients with metastatic breast cancer.
The timing of blood and plasma collection is obviously an important variable. In our study, all samples were collected immediately before the administration of each treatment cycle. The possibility of measuring an increase in the release of circulating tumor DNA as an indicator of responsiveness is attractive and is supported by xenograft models. (Table 1) . Globalization and climate change promote the emergence of these infections synergistically. Globalization increases the number of infected travelers and the accidental importation of infected vectors. Climate change warms the environment to temperatures that permit reproduction of the vector and parasite. Increasing 
